Revenues
SHLS
Shoals Technologies Group Inc (NASDAQ:SHLS) has received 11 analyst ratings in the last three months, with sentiments ranging from bullish to bearish. The average 12-month price target is $24.82, with a high of $33.00 and a low of $17.00, reflecting a 6.09% decrease from the previous average. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Shoals Technologies Gr specializes in EBOS solutions for solar energy projects and has recently entered the electric vehicle charging market. The company's financials show a revenue growth of 47.77% as of September 30, 2023, but it faces challenges with below-average ROE and ROA, despite efficient cost management and a conservative debt approach.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 7:01 pm
MPW
Medical Properties Trust (NYSE:MPW) has received mixed evaluations from 5 analysts in the past three months, with recent ratings showing 2 indifferent and 3 somewhat bearish stances. The average 12-month price target is now $4.9, a significant drop from the previous average, with individual targets ranging from $4.00 to $7.00. Analysts from firms including Mizuho, JP Morgan, Stifel, and Wells Fargo have lowered their price targets, reflecting a cautious outlook on the company's performance. Despite challenges in revenue growth, MPW exhibits strong profitability with a high net margin and ROE, and efficient asset use as indicated by its ROA. The company's debt-to-equity ratio is also below industry average, suggesting a healthier balance sheet.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 7:00 pm
AMBA
Ambarella (NASDAQ:AMBA) received mixed analyst ratings in the latest quarter with 10 analysts providing their perspectives. The average 12-month price target is $74.2, a slight decrease from the previous $74.83. Analysts from firms like Wells Fargo, Rosenblatt, Susquehanna, Morgan Stanley, Needham, and Stifel have updated their ratings and price targets, reflecting their views on the company's performance and market conditions. Ambarella, a developer of semiconductor processing solutions, faces challenges with a revenue decline of -39.11% over 3 months, a net margin of -82.44%, and below-average ROE and ROA. However, its debt-to-equity ratio is conservative at 0.01.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 7:00 pm
EOG
14 financial analysts have recently provided mixed evaluations of EOG Resources (NYSE:EOG), with a range of bullish to indifferent ratings. The average 12-month price target for EOG is now $149.0, down from $154.92, with individual analyst actions including both lowered and raised price targets and ratings. EOG Resources, an oil and gas producer, reported a -19.54% decline in revenue growth as of September 30, 2023, but has strong profitability indicators such as a net margin of 33.21% and ROE of 7.52%. The company's debt-to-equity ratio is also below the industry average, indicating less reliance on debt financing.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 7:00 pm
NYCB
New York Community (NYSE:NYCB) has received mixed reviews from 8 analysts in the last three months, with an average 12-month price target of $10.81, down 16.85% from the previous average. Analysts from firms including Wedbush, Keefe, Bruyette & Woods, Citigroup, Morgan Stanley, and Raymond James have adjusted their ratings and price targets, reflecting a cautious outlook on the bank's performance. Despite a significant revenue growth of 203.79% over the past 3 months, NYCB faces challenges with below-average net margin, ROE, ROA, and a high debt-to-equity ratio.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 7:00 pm
FUJHY
Subaru of America reported a 1.8% increase in vehicle sales for December 2023, with 57,764 vehicles sold compared to December 2022. The year-end sales for 2023 were up by 13.6%, as detailed in their press release.
Portfolio Pulse from
Benzinga Newsdesk
January 03, 2024 | 6:06 pm
RCM
R1 RCM (NASDAQ:RCM) has been analyzed by 10 analysts, showing a mix of bullish and bearish sentiments. The average 12-month price target is now $17.05, down from $19.70, with a high estimate of $20.00 and a low of $11.00. Analysts from firms like Barclays, Morgan Stanley, JP Morgan, RBC Capital, Canaccord Genuity, Cantor Fitzgerald, Keybanc, and Truist Securities have provided various ratings and price target adjustments. R1 RCM offers technology-driven solutions for healthcare providers and has shown a revenue growth of 15.6% as of September 30, 2023. However, its ROE and ROA are below industry averages, while its net margin is above average, and it has a sound debt-to-equity ratio.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 6:01 pm
WELL
Welltower (NYSE:WELL) has been evaluated by 8 financial analysts over the last three months, with a mix of bullish to bearish sentiments. The average 12-month price target is $94.88, up 5.76% from the previous $89.71. Analysts from firms like Mizuho, JP Morgan, RBC Capital, Evercore ISI Group, Wells Fargo, Raymond James, and Keybanc have raised their price targets, reflecting a positive outlook. Welltower's financials show a strong market presence, solid revenue growth, but challenges in profitability and return on equity, while excelling in asset utilization and maintaining a healthy debt-to-equity ratio.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 6:00 pm
BDX
Analysts have recently provided mixed reviews on Becton Dickinson (NYSE:BDX), with 4 somewhat bullish ratings in the past three months. The average 12-month price target has been lowered to $276.00 from $297.00, indicating a 7.07% decrease. Analysts from Raymond James and Piper Sandler have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Becton Dickinson is a major medical surgical products manufacturer, with BD Medical, BD Life Sciences, and BD Interventional as its business segments. The company's financials show solid revenue growth but below-average profitability and efficiency metrics.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 6:00 pm
SBRA
Sabra Health Care REIT (NASDAQ:SBRA) has received varied analyst ratings over the past three months, with 5 analysts offering ratings ranging from bullish to indifferent. The average 12-month price target has increased to $15.8, up 12.86% from the previous target of $14.00. Analysts from Mizuho, Stifel, Wells Fargo, and BMO Capital have raised their price targets and ratings, reflecting positive sentiment towards SBRA's stock. Sabra Health Care REIT, a healthcare facility REIT, has shown a revenue growth of 14.82% as of September 30, 2023, but struggles with below industry average net margin, ROE, and ROA, while maintaining a prudent debt-to-equity ratio of 0.82.
Portfolio Pulse from
Benzinga Insights
January 03, 2024 | 6:00 pm
Previous
Next
